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ABSTRACT
Background: Lung cancer is the most frequently diagnosed cancer and one of the top cause of
cancer death worldwide. The recent discovery of PIWI-interacting RNAs (piRNAs), one type of
non-coding RNAs, has been shown to be involved in tumorgenesis pathways of various types of
cancer types by accumulating evidences. However, the role of piRNAs in lung cancer
development is underexplored.
Methods: Genotype and phenotype data were obtained from a genome-wide association study of
lung cancer risk (3,702 cases and 3,739 controls) and 1,173 imputed piRNAs variants were
analyzed by association analysis for lung cancer risk. A secondary expression analysis is also
performed for 200 piRNAs to compare their expression levels in 497 lung adenocarcinoma
patients versus 46 normal controls. Following in vitro functional analysis was also performed for
the piRNAs variants identified from the association analysis.
Results: In the association analysis, one SNP (rs1169347) which can be mapped to two piRNAs
(piR-5247 and piR-5671) was identified as statistically significantly associated with lung caner
risk (FDR P-value <0.05). In the following functional analysis, results from cell viability assay
showed a cell-growth-promoting effect of the major allele of the identified SNP. In the
secondary expression analysis, 5 piRNAs were found significantly over-expressed in lung
adenocarcinoma patients.
Conclusions: This comprehensive post-GWAS study provided important evidences for the role
of piRNAs in lung cancer development through either their own functions or interactions with
other protein-coding genes.
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Introduction
Lung cancer is the most frequently diagnosed cancer and the first and second leading
cause of cancer death among males and females worldwide1. In the United States, there will be
an estimation of 224,390 new cases and 158,080 new deaths of lung cancer in 20162. Moreover,
the 5-year relative survival rate for lung cancer was only 18.4% from 2005 to 20113.
Currently, for non-small-cell lung cancer patients, which accounts for 85% of lung cancer
cases, the main treatment options are surgery, radiotherapy and adjuvant chemotherapy4.
However, since each treatment has its unavoidable side effects, a breakthrough in lung cancer
treatment to increase the survival rate as well as improve the quality of life for lung cancer
patients is needed. The advent of targeted therapy makes it possible to reduce the toxicity to
patients compared to cytotoxic drugs5. Therefore, to discover novel agents with clinical
significance that can be served as target for treatment of lung cancer in the future is especially
important.
In recent years, increasing evidences suggested that the non-protein-coding portion of the
genome is of crucial functional importance for disease development, including cancer6. Many
studies suggested that the non-coding RNAs (ncRNAs) function through modulation of
transcriptional or posttranscriptional processes7. Such transcriptional and posttranscriptional
modifications would lead to a highly conserved pathway in which the small non-coding RNAs
(sncRNAs) bind to protein complexes (PPD or Argonaute) and form the RNA-induced silencing
complexes (RISC) to inhibit the expression of its target sequences8. The main small silencing
RNAs can be classified into 3 categries: small interfering RNAs (siRNAs), microRNAs
(miRNAs) and PIWI-interacting RNAs (piRNAs)9.
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The length of piRNA sequence is between 26 and 31 nucleotides (nt), slightly longer
than siRNAs and miRNAs (between 21 and 26 nt)10. The primary function of piRNAs is to
stabilize the germ line genome by silencing the transposon elements (TEs) through a highly
conserved pathway which doesn’t require Dicer during the process, while miRNAs or siRNAsinduced silencing pathways require Dicer9. Besides the TE-silencing function of piRNAs in the
germ line, a growing number of studies are investigating its role in somatic cells. The detection
of 4 main types of Piwi proteins (PIWIL1/HIWI, PIWIL2/HILI, PIWIL 3, and PIWIL4) in
mammalian somatic tissues provides evidence for the existence of somatic piRNAs11. There are
two pathways for the biogenesis of somatic piRNAs. In the primary processing pathway, long
piRNA precursors are transcribed from piRNA clusters, cleaved and midified in the cytoplasma,
and then transported into the nucleus loaded with Aubergine (AUB) or PIWI proteins11. In the
amplification loop (ping-pong cycle), which is activated by piRNA-induced silencing complexes
(piRISCs) produced in the primary pathway, piRNAs are modified and amplified to target on
active TEs through a slicer-mediated cleavage9. Moreover, the PIWI-piRNAs pathway can
regulate the transposon loci or even non-transposon loci outside the germline tissues through
histone modifications and DNA methylation12.
Recent studies found that piRNAs and piRNA-like transcripts are involved in
tumorigenesis in a range of tumor types13. Both oncogenic and tumor-suppressing roles of
piRNAs have been found by microarray screening, next generation sequencing (NGS), and realtime quantitative reverse transcription-polymerase (PCR) chain reaction analyses14. Several
preliminary studies discovered the over-expression of PIWI proteins in several tumor types, such
as seminomas, breast cancer, cervical cancer, glioma, colon cancer, etc15,16,17,18,19. One possible
mechanism proposed by Siddiqi et.al20 was that the presence of piRNAs and PIWI proteins in the
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cancer tissues would result in aberrant DNA methylation and over-silencing of the promoting
regions of tumor suppressor genes, and then trigger the tumorgenesis. Therefore, piRNAs have
high potential to be a new prognostic biomarker or new therapy target for various types of
cancer.
To our knowledge, there are very few previous studies investigating the association
between piRNAs and lung cancer risk. Therefore, the aim of this study was to examine whether
piRNAs variants are associated with lung cancer risk. We used the data of 3,817 cases and 3,921
controls from three cohort studies21. In addition, we further tested the role of the identified single
nucleotide polymorphisms (SNPs) through in vitro functional analysis. Finally, we also
identified several piRNAs that are significantly different expressed in lung adenocarcinoma
compared to normal lung tissues by conducting a secondary analysis using the data derived from
a scientific report of piRNAs expression profiling in several tumor types22.

Materials and Methods
Study population and data
The population of this study is derived from a genome-wide association study of lung
cancer21, in which the subjects are from three cohort studies – Alpha-Tocopherol, Beta-Carotene
Cancer Prevention Study (ATBC)23, the Prostate, Lung, Colon, Ovary Screening Trial (PLCO)24,
and the Cancer Prevention Study II Nutrition Cohort (CPS-II)25. The accessible individual
genotype and phenotype data are downloaded from Database of Genotypes and phenotypes
(dbGaP, Study Accession: phs000336.v1.p1) to a secure server at Yale University and decrypted
and extracted according to dbGaP guidelines. The total population of this study is 7738, with
3,817 cases and 3,921 controls.
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In the secondary expression data analysis, 252 piRNAs for 497 lung adenocarcinoma
patients and 46 controls are obtained from the supplemental table 2 of the scientific report22. The
unit of piRNAs expression is defined as reads per kilobase per million mapped reads (RPKM)
and all RPKM values are obtained from the scientific report.

Data Cleaning and Management
All processes of data cleaning and management are performed by PLINK v 1.0726.
Subjects from the three studies are genotyped on one of the four platforms (Illumina
Human240K300K, HumanHap550K, Human610Quadv1, and Human1M-Duov3). The data of
539,000 SNPs in 3,817 cases and 3,921 controls are merged into one complete dataset. 124 pairs
of subjects were found to have a familial relationship by identity by by descent (IBD) analysis
(pi-hat (π) >= 0.2) and each member of the 124 pairs was excluded from the final analysis. The
dataset was restricted to SNPs with call rate ≥ 90% and Hardy-Weinberg Equilibrium test
(HWE) P > 0.0001. Then, principal components analysis (PCA) was carried out using
EIGENSTRAT27 and 173 subjects were excluded as outliers. Finally, the sample file contained
533,002 SNPs in 3702 cases and 3739 controls.
For the expression data, 52 piRNAs were excluded from the final analysis because 13 of
these piRNAs are mapped with overlaps to microRNAs (miRNAs), 36 are mapped to small
nucleolar RNAs (snoRNAs), and 3 are mapped to transfer RNAs (tRNAs). After confirming the
correct mapping by piRNABank and UCSC genome browser, 200 piRNAs were included in the
final analysis.
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piRNA Variant Genotype Imputation
The piRNA SNP list including the copy number and genome loci is obtained from
piRNABank28. SNPs with copy number >100 were excluded because evidence showed that
piRNAs with lower copy number are more likely to be involved in the regulation of proteincoding gene expression29. The 1,000 Genomes Phase 3 haplotype data were used as reference
panel for imputation30. The imputation was performed using IMPUTE v2.3.1 software31. Fine
mapping was performed through imputation of all SNPs with minor allele frequency
(MAF) >1% in 5MB segments and all the coordinates information are collected from Genome
Reference Consortium GRCh37/hg19 on USCS genome browser32.

Association Analyses
The statistical analysis of the association study was performed by SNPTEST v2.533 using
unconditional regression regression and the additive allele model, controlling for sex, age,
original study participation, genotyping platform, and the first two principal components. The
number of the principal components to control is determined by the study-wide genomic
inflation-factor (GIF) and the corresponding QQ plot. The odds ratio (OR), 95% confidence
interval (95% CI), nominal p-value, and false discovery rate-adjusted (FDR) P-value is provided
for every association. The Manhattan plot and QQ plot are generated by R using qqman
package34.

Comparison of piRNAs expression level between normal and lung adenocarcinoma samples
A scatter plot visualizing the different expression level of the 200 included piRNAs
between samples from 497 lung adenocarcinoma patients and 46 controls was created by J-
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Express software35. The 2-tail t-test was used to detect the difference of individual piRNA
expression level between samples from 497 lung adenocarcinoma patients and 46 controls for the
200 included piRNAs. Bonferroni-adjustment for multiple comparisons has been applied.

Materials for Functional Analyses
Human lung carcinoma epithelial cells (A549) are purchased from ATCC and are
maintained in F-12K medium supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin. The wild type piRNA mimics of the two identified piRNAs, piRNA-5247 and piRNA5671, were purchased from IDT, and the negative control non-targeting RNA were purchased
from QIAGEN. Cells were transfected using LipofectAMINE RNAiMAX transfection reagent.
The transfection rate was close to 100% as detected in our lab, and the toxicity of the transfection
reagent showed little impact on the cell growth.

Cell Viability Assay
Cells are treated as triplicates for piRNA-5247, piRNA-5671 and the negative control
RNA in the 96-well plate and the cell viability was evaluated by the CellTiter 96 AQueous One
Solution Cell Proliferation Assay (MTS) kit (Promega). In one transfection experiment setting, 3
readings will be recorded by a microplate spectrophotometer at an absorbance of 490nm at 48,
72 and 96 hours, respectively. The different impact of the three RNAs on cell viability was
determined by 2-tail t-test.
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Results
Two identified piRNAs associated with lung cancer risk
The baseline characteristics of the included 3,702 cases and 3,739 controls are showed
in Table 1. There are more males in control group than case group. The age distribution is similar
between the two groups. A larger proportion of controls are from PLCO study while more cases
are from ATBC study. And samples from the cases are mostly genotyped on HumanHap550K
and Human610Quadv1 array whereas controls are genotyped on all the four arrays.
After all the data cleaning processes, genotype data of 533,002 SNPs from a total
population of 7,441 have been included in the PCA analysis. A total of 1,173 SNPs that can be
mapped to piRNAs of our interest are successfully imputed and included into the final
association studies. The association between these 1,173 variants and lung cancer risk is
displayed in a Manhattan Plot (Figure 1a). After adjusting for multiple comparisons by
Bonferroni-correction, only one SNP (rs11639347) is statistically significant associated with
lung cancer risk. rs11639347 can be mapped to two overlapping piRNAs, piR-5247 and piR5671. As showed in Table 2, the minor allele of rs11639347 is a risky allele that increases lung
cancer risk with an odds ratio (OR) of 1.17 (95% confidence interval (CI): 1.09, 1.27).
Information about the SNP name, mapped piRNAs, position, allele, minor allele frequency, OR,
nominal P-value, and FDR P-value for the top 3 identified SNPs are also included in Table 2.
The association analysis is controlled for sex, age, original study participation, genotyping
platform, and the first two principal components. A QQ plot (Figure 1b) demonstrating the
control for covariates included in the association analysis is provided. Moreover, a plot (Figure
2) displaying the PCA results for the 2 principal components in which original studies are
annotated in different colors is also provided.
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Functional role of the major allele of the two identified piRNAs
Wild-type mimics for piR-5247 and piR-5671 were delivered into A549 cell lines. A nontargeting RNA mimics were also delivered into A549 cell lines as negative controls. Figure 3
showed the sequence information of piR-5247 and piR-5671. The allele locus of rs11639347 was
highlighted as well. The transfection of each mimics has been done in triplicates. Figure 4a
shows the reading results at 48, 72, and 96 hours after transfection of the 3 mimics. Interestingly,
even if the wild-type allele of the two identified piRNAs has a protective role as indicated by the
association analysis, the cells transfected with piR-5247 and piR-5671 can still significantly
promote the A549 cell growth compared to negative-control RNA-treated A549 cells. Similarly,
the cell growth trend showed in Figure 4b also revealed a same function of the wild-type allele.

Individual piRNAs Expression Level Difference
The scatter plot (figure 5) shows the mean expression level of each individual piRNAs
among 497 lung adenocarcinoma patients and 46 normal controls. Most piRNAs have very low
expression level in both lung adenocarcinoma and normal samples. However, the expression
level was detectable in several outlying piRNAs which showed different expression patterns in
tumor samples compared to normal samples. The seven highest expressed piRNAs in tumor
samples have been listed in table 3. The information about the piRNA name, position, coding
region, mean expression level in normal samples, mean expression level in lung tumor samples,
nominal P-values generated by 2-tail t-test, and FDRP-values are provided. From table 2, 5
piRNAs (piR-14620, piR-2732, piR-51809, piR-19521, and piR-15232) are statistically
significantly different expressed between normal and tumor samples. Among them, piR-14620 is
of the highest expression level and all of the 5 piRNAs are up-regulated in tumor samples. The
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only piRNA that is down-regulated in tumor samples of the top 7 piRNAs was piR-31637.
However, after Bonferroni correction, the difference of its expression level was not statistically
significant.

Discussion
This is the first comprehensive post-GWAS study combining the results of association
analysis, the functional analysis and the expression profiling analysis to explore the involvement
of piRNAs in lung cancer development. From the association analysis, we have identified the
variant in one SNP (rs11639347) that is significantly associated with the increase risk of lung
cancer. The location of the variant (Chromosome 15: 79024350) and the 2 piRNAs, piR-5247
(Chromosome 15: 79024333-79024361) and piR-5671 (Chromosome 15: 79024327-79024355)
is in intergenic region. This suggests that the functional changes caused by the 2 piRNAs may be
attributed to their own functions. In addition, we established a follow-up in vitro functional
analysis to further explore the role of the two piRNAs in A549 cell growth. The cell viability
assay result shows a cell-growth promoting effect of the protective allele of rs11639347 on A549
lung cancer cell lines, suggesting that this SNP may play an oncogenic role in lung cancer
development. Moreover, we used the same experiment setting to transfect the U87 cells with the
2 piRNAs mimics, a glioma cell line. The result (data not shown) showed that the 2 piRNAs
have no effect on the growth of U87 cells. Therefore, these data suggest that the SNP
rs11639347 may be tissue-specific involved in the lung cancer development pathway. Further
functional analysis, such as cell viability assay, colony formation assay which is regarded as the
“gold standard” cellular-sensitivity assay36, and expression profiling should be conducted for the
risk allele (rs11639347).
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From the expression analysis, we have identified 5 piRNAs that are up-regulated in lung
adenocarcinoma samples. Among which, piR-14620, the highest expressed piRNA, is located in
the intron of gene KIAA0825. piR-2732 is located in the intron of gene RPL3, which encodes the
ribosome proteins and is involved in DNA repair through regulation of p21 function37. piR51809 is located in the intron of gene CPA6. piR-19521 is located in the intergenic region. piR15232 is located in the exon of HIST1H2BJ, which encodes H2B histone protein38. Therefore,
future studies are needed to explore the role of KIAA0825, CPA6 and HIST1H2BJ in lung
cancer development. Functional analysis of piR-2732 should be further conducted since it seems
be involved in cancer development through regulation of DNA repair and cell apoptosis.
There are several strengths of this study. First, in association study, the use of 1,000
Genome Phase 3 haplotype reference panel guarantees a wide coverage of piRNA embedded
SNPs during imputation. Second, the result of cell viability assay shows rs11639347 only
functions to promote the lung cancer cell growth, suggesting it may be a good specific target for
future lung cancer treatment. Third, from the association study and expression analysis, we’ve
identified several piRNAs variants associated with lung cancer risk are located in protein-coding
regions as well as intergenic regions. This finding provides further evidences to suggest that
piRNAs play important roles in tumorgenesis through either their independent biological roles or
interactions with oncogenes or tumor-suppressor genes. Lastly, the combination of association
study, expression analysis, and functional analysis provides a comprehensive understanding of
the identified SNPs that are associated with lung cancer risk.
While this study suggests a role of piRNAs in lung cancer development, there are some
limitations. First, even if the reference panel has a very wide coverage of SNPs, piRNAs variants
that are not included in the panel cannot be imputed. Therefore, a small part of piRNAs may be
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missing in this study. Second, in the expression analysis, we’ve found that some piRNAs
included in the original scientific report are actually overlapped with other types of small noncoding RNAs, leaving an inevitable potential mapping quality issue in our secondary analysis of
the expression data. However, we believe this issue has been minimized since we checked the
genomic loci of all the individual piRNAs and excluded those overlapped with other types noncoding RNAs. Third, due to the limited baseline characteristics of study participants provided by
dbGaP datasets, we are only able to control for the confounding effects of sex, age, original
study participation, genotyping platform.
Future work will focus on the functional analysis for the identified piRNAs variants from
both association and expression analysis. More specifically, for rs11639347, we will continue
analyze the function role of its risk allele in lung cancer cell-growth by cell-viability assay and
clonogenic assay. In addition, we will perform expression profiling of the 2 piRNAs embedded
in this SNP. Finally, we will further investigate the mechanism of the pathway it is involved in
lung tumorgenesis on protein-interaction level.
In conclusion, this comprehensive post-GWAS study provides strong evidence for an
association between piRNAs and lung cancer risk. The in vitro functional analysis provides
further evidences of an oncogenic role of piRNAs in lung cancer development. Future functional
work will help us to better understand the function of the identified piRNAs that may be
involved in lung tumorgenesis.
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Tables
Table 1: A table of baseline characteristics of included association study population. The
number of participants of each category for and the percentage for sex, age, study and array is
provided included. The percentage of each category in cases and controls is also included.
Characteristics

Cases (N=3702)

Controls (N=3739)

Male (%)
Female (%)

2873 (77.61%)
829 (22.39%)

3279 (87.70%)
460 (12.30%)

<50 (%)
50-54 (%)
55-59 (%)
60-64 (%)
65-69 (%)
70-74 (%)
75+ (%)

6 (0.16%)
457 (12.34%)
923 (24.93%)
1130 (30.52%)
853 (23.04%)
310 (8.37%)
23 (0.62%)

6 (0.16%)
427 (11.42%)
865 (23.13%)
1112 (29.74%)
909 (24.31%)
386 (10.32%)
34 (0.91%)

PLCO
CPSII
ATBC

1311 (35.41%)
663 (17.91%)
1728 (46.68%)

1819 (48.65%)
650 (17.38%)
1270 (33.97%)

Human240K300K
HumanHap550K
Human610Quadv1
1M-Duov3

0 (0%)
757 (20.45%)
2945 (79.55%)
0 (0%)

965 (25.81%)
829 (22.17%)
1797 (48.06%)
148 (3.86%)

Sex

Age

Study

Array
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Table 2: A table for summary of top-3 identified piRNAs embedded SNPs that are associated with lung cancer risk.
SNP

piRNAs1

Position

Minor/Common
Allele

MAF
(cases/controls)

OR2

95% CI

Nominal P-value

FDR P-value3

rs11639347

piR-5247
piR-5671

Chr15: 79024350

T/C

0.41/0.38

1.17

(1.09, 1.27)

3.560E-05

0.042

rs13382748

piR-21626

Chr2: 95450931

C/T

0.11/0.10

1.26

(1.12,1.43)

2.190E-04

0.257

rs60534722

piR-16828

Chr12: 24554473

A/G

0.17/9.19

0.85

(0.77,0.94)

1.498E-03

1.757

1

: Identified SNPs are located within the genome loci of the piRNAs; 2: Odds ratio for the minor allele associated with lung cancer; 3: Bonferroni-correction for 1173 comparisons.

Table 3: A table for summary data of top-7 identified piRNAs from the expression analysis.
piRNAs1

Name

Position

Strand

FR043670
FR090905
FR082269
FR205579
FR038165
FR111727
FR197889

piR-14620
piR-20009
piR-31637
piR-2732
piR-51809
piR-19521
piR-15232

Chr5: 93905174-93905200
Chr7: 145694484-145694511
ChrM: 619-650
Chr22: 39709883-39709914
Chr8:68497704-68497734
Chr11:10530940-10530967
Chr6:27100537-27100567

+
+
+

1

Gene2
Intron of KIAA0825
Intergenic
Intergenic
Intron of RPL3
Intron of CPA6
Intergenic
Exon of HIST1H2BJ

Mean-Normal3
486.94
389.33
358.28
26.71
3.22
6.07
4.56

MeanTumor4
1025.32
711.72
149.19
140.45
59.26
48.22
40.98

Nominal PValue
6.280E-05
0.047
0.005
1.060E-18
2.300E-16
6.540E-23
5.720E-41

: piRNAs name used in the scientific report; 2: The genome region where piRNAs are located; 3,4: The mean expression level (RPKM) of tumor and control
samples. 5: Bonferroni-correction for 200 comparisons.

FDR PValue5
0.001
9.391
1.090
2.120E-16
4.610E-14
1.310E-20
1.140E-38
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Figures

Figure 1a: A Manhattan plot displaying the results from association study for the 1,173 piRNAs
variants. The variant rs1169347 is annotated in the plot.
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Figure 1b: A QQ plot indicating the adjustment for covariates from the association study.
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Figure 2: A plot showing the first two principal components categorized by original studies from
the principal components (PCA) analysis.
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Figure 3: Sequence and genomic locus information for the wild-type and minor allele of
rs11639347 as well as the 2 embedded piRNAs (piR-5247 and piR5671).
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Figure 4a: The results of cell viability assay readings for NC-treated, piR-5247-treated and piR5671-trated A519 cells at 48, 72, and 96 hours respectively.
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Figure 4b: The time trend of A549 cell growth showing the effect of piR-5247 and piR-5671.
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Figure 5: A Scatter Plot displaying the results of the secondary expression. X-axis is the mean
expression level of each piRNAs in 46 normal samples while Y-axis is the mean expression level
of each piRNAs in 497 tumor samples
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